MET and non-small cell lung carcinoma: Savolitinib is an oral, ATP-competitive, type Ib MET TKI, with high selectivity for MET, approved on June 2021 in China for patients with advanced NSCLC with MET exon 14 skipping alterations with progression disease after prior systemic therapy or who are unable to receive chemotherapy [83,84].